New advances in antibiotic development and discovery

Expert Opinion on Investigational Drugs

Volumn 14, Issue 2, 2005, Pages 117-134

  Alekshun, Michael N ^a  

^a Transcept Pharmaceuticals Inc   (United States)

Author keywords

lactam; Antibiotic development; Antibiotic discovery; antibiotic resistance; Fluoroquinolone; Glycolipodepsipeptide; Ketolide; Macrolide; Multiple antibiotic resistance; Oxazolidinone; Peptide deformylase inhibitor; Rifamycin; Streptogramin; Tetracycline

Indexed keywords

ANTIBIOTIC AGENT; CEFDITOREN PIVOXIL; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; EP 13420; ERTAPENEM; FROPENEM; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GW 773546; ICLAPRIM; IMIPENEM; LINEZOLID; MACROLIDE; MOXIFLOXACIN; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; POSIZOLID; PRULIFLOXACIN; RAMOPLANIN; RANBEZOLID; RIFALAZIL; RIFAPENTINE; SITAFLOXACIN; TELAVANCIN; TELEVANCIN; TELITHROMYCIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIOSTASIS; BACTERIUM IDENTIFICATION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TOLERANCE; DRUG URINE LEVEL; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; LUNG TUBERCULOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NAUSEA; PENICILLIN RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 12744268873     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.2.117     Document Type: Review

References (144)

1. INFECTIOUS DISEASES SOCIETY OF AMERICA: Special report: bad bugs, no drugs: as antibiotic discovery stagnates...a public health crisis brews. (2004).
2. SPELLBERG B, POWERS JH, BRASS EP, MILLER LG, EDWARDS JE Jr: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38(9):1279-1286.
3. WENZEL RP: The antibiotic pipelinechallenges, costs, and values. N. Engl. J. Med. (2004) 351(6):523-526.
4. SHLAES DM: The abandonment of antibacterials: why and wherefore? Curr. Opin. Pharmacol. (2003) 3(5):470-473.
5. HIRAMATSU K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. (2001) 1(3):147-155.
6. NAIMI TS, LEDELL KH, COMO-SABETTI K et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA (2003) 290 22):2976-2984.
7. KARLOWSKY JA, THORNSBERRY C, JONES ME, SAHM DF: Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin. Infect. Dis. (2003) 36(2):183-187.
8. LEVIN AS, BARONE AA, PENCO J et al.: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. (1999) 28(5):1008-1011.
9. ELIOPOULOS GM: Current and new antimicrobial agents. Am. Heart J. (2004) 147(4):587-592.
10. MEKA VG, GOLD HS: Antimicrobial resistance to linezolid. Clin. Infect. Dis. (2004) 39(7):1010-1015.
11. MANDELL LA, BARTLETT JG, DOWELL SF et al.: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. (2003) 37 11):1405-1433.
12. ZHANEL GG, HOMENUIK K, NICHOL K et al.: The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 64(1):63-88.
13. ZHANG YY, ZHOU L, ZHU DM et al.: In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn. Microbiol. Infect. Dis. (2004) 50(4):267-281.
14. 2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. (2004) 53(4):592-599.
15. FRITSCHE TR, JONES RN: Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int. J. Antimicrob Agents (2004) 24(6):567-571.
16. HERRERO IA, ISSA NC, PATEL R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. (2002) 346(11):867-869.
17. MURALIDHARAN G, MICALIZZI M, SPETH J, RAIBLE D, TROY S: Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. (2005) 49 1):220-229.
18. POSTIER RG, GREEN SL, KLEIN SR, ELLIS-GROSSE EJ, LOH E: Results of a Multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. (2004) 26 5):704-714.
19. DARTOIS N, TIGECYCLINE 305 cSSSI STUDY GROUP: Results of a Phase III, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin-structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
20. MACONE A, DONATELLI J, DUMONT T, LEVY SB, TANAKA SK: In vitro activity of PTK 0796 against Gram-positive and Gram-negative organisms. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
21. BRÖETZ-OESTERHELT H, ENDERMANN R, LADEL CH, LABISCHINSKI H: Superior efficacy of BAY 73-7388, a novel aminomethylcycline, compared with linezolid and vancomycin in murine sepsis caused by susceptible or multiresistant staphylococci. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (2004).
22. McKENNEY D, QUINN JM, JACKSON CL et al.: Evaluation of PTK 0796 in experimental models of infections caused by Gram-positive and Gram-negative pathogens. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
23. McKENNEY D, QUINN JM, JACKSON CL et al.: The efficacy of PTK 0796 in murine models of Streptococcus pneumoniae. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
24. ENDERMANN R, LADEL CH, BROETZ-OESTERHELT H, LABISCHINSKI H: BAY 73-7388 is highly efficacious in animal models of intra-abdominal infections caused by a range of aerobic and anaerobic organisms, including VRE. 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic (2004).
25. PAGE MG: Cephalosporins in clinical development. Expert Opin. Investig. Drugs (2004) 13(8):973-985.
26. HEBEISEN P, HEINZE-KRAUSS I, ANGEHRN P et al.: In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. (2001) 45(3):825-836.
27. SCHMITT-HOFFMANN A, NYMAN L, ROOS B et al.: Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48(7):2576-2580.
28. SCHMITT-HOFFMANN A, ROOS B, SCHLEIMER M et al.: Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. (2004) 48(7):2570-2575.
29. HEEP M, QUERNER S, HARSCH M, O'RIORDAN W: Ceftobiprole (BAL-5788), the first of a new class of anti-MRSA cephalosporins-microbiological results from a Phase II study in complicated skin and skin-structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
30. TSUJI M, ISHII Y, OHNO A, MIYAZAKI S, YAMAGUCHI K: In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. (1998) 42(1):94-99.
31. JONES RN, HUYNH HK, BIEDENBACH DJ: Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. (2004) 48(8):3136-3140.
32. GE Y, WIKLER MA, SAHM DF, BLOSSER-MIDDLETON RS, KARLOWSKY JA: In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. (2004) 48(4):1384-1396.
33. MASUDA N, SAKAGAWA E, OHYA S et al.: Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2000) 44 12):3322-3327.
34. MUSHTAQ S, GE Y, LIVERMORE DM: Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. (2004) 48 8):3086-3092.
35. FLOREN L, WIKLER M, KILFOIL T, GE Y: A Phase I, double-blind, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC (2004).
36. FLOREN L, WIKLER M, KILFOIL T, GE Y: A Phase I open-label controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC (2004).
37. NAKAJIMA Y, MIZOBUCHI M, NAKAMURA M et al.: Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab. Dispos. (2004) 32 12):1383-1391.
38. BUSH K, MACIELAG M, WEIDNER-WELLS M: Taking inventory: antibacterial agents currently at or beyond Phase I. Curr. Opin. Microbiol. (2004) 7(5):466-476.
39. THOMSON KS, MOLAND ES: CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J. Antimicrob. Chemother. (2004) 54(2):557-562.
40. JACOBS MR, BAJAKSOUZIAN S, WINDAU A et al.: In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob. Agents Chemother. (2004) 48(9):3338-3342.
41. PERIC M, JACOBS MR, APPELBAUM PC: Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared with those of nine other agents. Antimicrob. Agents Chemother. (2004) 48(8):3188-3192.
42. MAHARAJ N, JHA R, CHUGH Y et al.: A phase-I study of escalating single doses of intravenous (IV) WCK 771. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
43. MILATOVIC D, SCHMITZ FJ, BRISSE S, VERHOEF J, FLUIT AC: In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob. Agents Chemother. (2000) 44(4):1102-1107.
44. DALHOFF A, SCHMITZ FJ: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbio. Infect. Dis. (2003) 22(4):203-221.
45. DAWE RS, IBBOTSON SH, SANDERSON JB, THOMSON EM, FERGUSON J: A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br. J. Dermatol. (2003) 149(6):1232-1241.
46. SHETTY N, WILSON AP: Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (2000) 46(4):633-638.
47. GAJJAR DA, BELLO A, GE Z, CHRISTOPHER L, GRASELA DM: Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob. Agents Chemother. (2003) 47 7):2256-2263.
48. VAN WART S, PHILLIPS L, LUDWIG EA et al.: Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. (2004) 48(12):4766-4777.
49. PANKUCH GA, KELLY LM, LIN G et al.: Activities of a new oral streptogramin, XRP 2868, compared with those of other agents against Streptococcus pneumoniae and Haemophilus species. Antimicrob. Agents Chemother. (2003) 47(10):3270-3274.
50. KOSOWSKA K, CREDITO K, PANKUCH GA et al.: Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. Antimicrob. Agents Chemother. (2004) 48 11):4113-4119.
51. MATIC V, KOSOWSKA K, BOZDOGAN B et al.: Anti-pneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Antimicrob. Agents Chemother. (2004) 48(11):4103-4112.
52. SCORNEAUX B, ARYA A, POLEMEROPOULOS A et al.: In vitro and in vivo evaluation of EP-13420: a novel ketolide highly active against resistant pathogens and having exceptional pharmacokinetic properties in the dog. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
53. XIONG L, KORKHIN Y, MANKIN AS: Binding site of the bridged macrolides in the Escherichia coli ribosome. Antimicrob. Agents Chemother. (2005) 49(1):281-288.
54. EGGERT US, RUIZ N, FALCONE BV et al.: Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin. Science (2001) 294(5541):361-364.
55. ALEKSHUN MN: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy: an update on new antibiotics, novel non-antibacterial treatment modalities and critical issues in antibiotic resistance. Expert Opin. Investig. Drugs (2005) 14(1):93-99.
56. VAN BAMBEKE F: Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. (2004) 4(5):471-478.
57. DOWELL JA, SELTZER E, BUCKWALTER M, MARBURY T: The pharmacokinetics of dalbavancin (DAL) in subjects wilt mild, moderate or severe hepatic impairment (HI). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
58. BHAVNANI SM, PASSARELL JA, OWEN JS et al.: Pharmacokinetic pharmacodynamic (PK/PD) analysis and efficacy of oritavancin in patients with Staphylococcus aureus (SA) bacteremia. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC, USA (2004).
59. SHAW JP, SEROOGY J, KANIGA K et al.: Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. (2005) 49 1):195-201.
60. BARRIERE S, GENTER F, SPENCER E et al.: Effects of a new antibacterial, telavancin, on cardiac repolarisation (QTc interval duration) in healthy subjects. J. Clin. Pharmacol. (2004) 44 7):689-695.
61. MONTECALVO MA: Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J. Antimicrob. Chemother. (2003) 51 Suppl. 3):iii31-iii35.
62. SCHNEIDER P, HAWSER S, ISLAM K: Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. (2003) 13 23):4217-4221.
63. KOHLHOFF SA, ROBLIN PM, REZNIK T et al.: In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob. Agents Chemother. (2004) 48(5):1885-1886.
64. DARST SA: New inhibitors targeting bacterial RNA polymerase. Trends Biochem. Sci. (2004) 29(4):159-160.
65. ROTHSTEIN DM, HARTMAN AD, CYNAMON MH, EISENSTEIN BI: Development potential of rifalazil. Expert Opin. Investig. Drugs (2003) 12(2):255-271.
66. DIETZE R, TEIXEIRA L, ROCHA LM et al.: Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. (2001) 45 7):1972-1976.
67. BATTEIGER B, McCORMACK W, STAMM W: A double-blind, randomomised trial of rifalazil (Rif) for the treament of nongonococcal urethritis (NGU) and chlamydial infection. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004).
68. BLASI F, TARSIA P, COSENTINI R, VALENTI V: Newer antibiotics for the treatment of respiratory tract infections. Curr. Opin. Pulm. Med. (2004) 10(3):189-196.
69. EDNIE LM, RATTAN A, JACOBS MR, APPELBAUM PC: Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob. Agents Chemother. (2003) 47(3):1143-1147.
70. HOELLMAN DB, LIN G, EDNIE LM et al.: Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob. Agents Chemother. (2003) 47(3):1148-1150.
71. MATHUR T, BHATEJA P, PANDYA M, FATMA T, RATTAN A: In vitro activity of RBx 7644 (ranbezolid) on biofilm, producing bacteria. Int. J. Antimicrob. Agents (2004) 24(4):369-373.
72. FLUIT AC, SCHMITZ FJ, VERHOEF J, MILATOVIC D: In vitro activity of AZD-2563, a novel oxazolidinone, against European Gram-positive cocci. J. Antimicrob. Chemother. (2002) 50 (2):271-276.
73. WOOKEY A, TURNER PJ, GREENHALGH JM et al.: AZD-2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Clin. Microbiol. Infect. (2004) 10 3):247-254.
74. YONG D, YUM JH, LEE K et al.: In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. (2004) 48(1):352-357.
75. ACKERMANN G, LOFFLER B, ADLER D, RODLOFF AC: In vitro activity of OPT-80 against Clostridium difficile. Antimicrob. Agents Chemother. (2004) 48(6):2280-2282.
76. CREDITO KL, APPELBAUM PC: Activity of OPT-80, a novel macrocycle, compared to those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. (2004) 48 11):4430-4434.
77. SHANGLE S, LEE C, OKUMU F et al.: Safety and pharmacokinetics of OPT-80 in human volunteers. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
78. WALLER AS, CLEMENTS JM: Novel approaches to antimicrobial therapy: peptide deformylase. Curr. Opin. Drug Discov. Devel. (2002) 5(5):785-792.
79. EDNIE LM, PANKUCH G, APPELBAUM PC: Antipneumococcal activity of LBM-415, a new peptide deformylase inhibitor, compared to those of other agents. Antimicrob. Agents Chemother. (2004) 48 10):4027-4032.
80. CREDITO K, LIN G, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of LBM-415, a new peptide deformylase inhibitor, compared to those of other agents. Antimicrob. Agents Chemother. (2004) 48 10):4033-4036.
81. CHEN D, HACKBARTH C, NI ZJ et al.: Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. (2004) 48(1):250-261.
82. APFEL CM, LOCHER H, EVERS S et al.: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. (2001) 45 4):1058-1064.
83. MARGOLIS PS, HACKBARTH CJ, YOUNG DC et al.: Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. (2000) 44(7):1825-1831.
84. WISE R, ANDREWS JM, ASHBY J: In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46(4):1117-1118.
85. LOFLAND D, DIFUNTORUM S, WALLER A et al.: In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J. Antimicrob. Chemother. (2004) 53(4):664-668.
86. RAMANATHAN-GIRISH S, McCOLM J, CLEMENTS JM et al.: Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2004) 48 12):4835-4842.
87. COKER RJ: Review: multidrug-resistant tuberculosis: public health challenges. Trop. Med. Int. Health (2004) 9(1):25-40
88. ANDRIES K, VERHASSELT P, GUILLEMONT J et al.: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2005) 307(5707):223-227.
89. BEGLEY TP, KINSLAND C, STRAUSS E: The biosynthesis of coenzyme A in bacteria. Vitam. Horm. (2001) 61:157-171.
90. GERDES SY, SCHOLLE MD, D'SOUZA M et al.: From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. (2002) 184 16):4555-4572.
91. CHOUDHRY AE, MANDICHAK TL, BROSKEY JP et al.: Inhibitors of pantothenate kinase: novel antibiotics for staphylococcal infections. Antimicrob. Agents Chemother. (2003) 47 6):2051-2055.
92. BEYER D, KROLL HP, ENDERMANN R et al.: New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity. Antimicrob. Agents Chemother. (2004) 48 2):525-532.
93. GUILES JW, TARASOW T, QIU J et al.: Novel thiophene-containing inhibitors of bacterial methionyl tRNA synthetase: improved activity resulting from fluorovinylthiophene replacement of arylbromides. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
94. CRITCHLEY IA, STONE K, YOUNG C et al.: REP8839: a novel methionyl tRNA synthetase inhibitor with potent activity against Staphylococcus aureus and Streptococcus pyogenes. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
95. HEATH RJ, ROCK CO: Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs (2004) 5 2):146-153.
96. McMURRY LM, OETHINGER M, LEVY SB: Triclosan targets lipid synthesis. Nature (1998) 394:531-532.
97. HEATH RJ, ROCK CO: A triclosan-resistant bacterial enzyme. Nature (2000) 406(6792):145-146.
98. FREIBERG C, BRUNNER NA, SCHIFFER G et al.: Identification and characterisation of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J. Biol. Chem. (2004) 279(25):26066-26073.
99. LIVERMORE DM: Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. (2003) 51 (Suppl. 2):ii9-ii16.
100. POOLE K: Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob. Agents Chemother. (2000) 44 9):2233-2241.
101. GORDEEV MF, HACKBARTH C, BARBACHYN MR et al.: Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg. Med. Chem. Lett (2003) 13(23):4213-4216.
102. LI Q, LEE JY, CASTILLO R et al.: NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against β-lactamase-producing strains. Antimicrob. Agents Chemother. (2002) 46(5):1262-1268.
103. STONE GW ZHANG Q, CASTILLO R et al.: Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by β-lactamases. Antimicrob. Agents Chemother. (2004) 48 2):477-483.
104. TEDDER ME, NIE Z, MARGOSIAK S et al.: Structure-based design, synthesis, and antimicrobial activity of purine derived SAH/MTA nucleosidase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14 12):3165-3168.
105. LI X, CHU S, FEHER VA et al.: Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitors. J. Med. Chem. (2003) 46 26):5663-5673.
106. LOWE J, VAN DEN ENT F, AMOS LA: Molecules of the bacterial cytoskeleton. Ann. Rev. Biophys. Biomol. Struct. (2004) 33 177-198.
107. WANG J, GALGOCI A, KODALI S et al.: Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J. Biol. Chem. (2003) 278 45):44424-44428.
108. MARGALIT DN, ROMBERG L, METS RB et al.: Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl. Acad. Sci. USA (2004) 101(32):11821-11826.
109. WHITE EL, SULING WJ, ROSS LJ, SEITZ LE, REYNOLDS RC: 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J. Antimicrob. Chemother. (2002) 50(1):111-114.
110. DANDLIKER PJ, PRATT SD, NILIUS AM et al.: Novel antibacterial class. Antimicrob. Agents Chemother. (2003) 47 12):3831-3839.
111. CLARK RF, WANG S, MA Z et al.: Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variants. Bioorg. Med. Chem. Lett (2004) 14(12):3299-3302.
112. JAYASEKERA MM, ONHEIBER K, KEITH J et al.: Identification of novel inhibitors of bacterial translation elongation factors. Antimicrob. Agents Chemother. (2005) 49(1):131-136.
113. DRLICA K, ZHAO X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol. Biol. Rev. (1997) 61(3):377-392.
114. NAKADA N, SHIMADA H, HIRATA T et al.: Biological characterisation of cyclothialidine, a new DNA gyrase inhibitor. Antimicrob. Agents Chemother. (1993) 37(12):2656-2661.
115. ANGEHRN P, BUCHMANN S, FUNK C et al.: New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine. J. Med. Chem. (2004) 47(6):1487-1513.
116. YAGER KM, ALMASSY B, BENSEN D et al.: Structure-based discovery and optimisation of novel antibacterials directed against DNA topoisomerases. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
117. GRILLOT A, STAMOS D, GROSSMAN T et al.: A new class of dual targeting inhibitors of GyrB and ParE. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
118. ARTSIMOVITCH I, CHU C, LYNCH AS, LANDICK R: A new class of bacterial RNA polymerase inhibitor affects nucleotide addition. Science (2003) 302(5645):650-654.
119. LEPING L, CHEN X, CUTLER ST: Pyrazole antimicrobial agents US patent application 2002/0049205 (2002).
120. LEPING L, CHEN X, FAN P, MIHALIC JT, CULTER S: Antimicrobial agents US patent application 2002/0045749 (2002).
121. BENTLEY R: The shikimate pathway - a metabolic tree with many branches. Crit. Rev. Biochem. Mol. Biol. (1990) 25 5):307-384.
122. BULLOCH EM, JONES MA, PARKER EJ et al.: Identification of 4-amino-4-deoxychorismate synthase as the molecular target for the antimicrobial action of (6s)-6-fluoroshikimate. J. Am. Chem. Soc. (2004) 126(32):9912-9913.
123. KUNTZ L, TRITSCH D, GROSDEMANGE-BILLIARD C et al.: Isoprenoid biosynthesis as target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase. Biochem. J. (2004) (In Press).
124. BERTINO J, GREEN L, LIN Y et al.: DNA polymerase III holoenzyme (Pol III HE) as a platform for the discovery of new anti-infective agents. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2004).
125. TIMSON DJ, SINGLETON MR, WIGLEY DB: DNA ligases in the repair and replication of DNA. Mutat Res. (2000) 460(3-4):301-318.
126. +-dependent DNA ligase from Staphylococcus aureus. J. Bacteriol. (2001) 183(10):3016-3024.
127. CIARROCCHI G, MacPHEE DG, DEADY LW, TILLEY L: Specific inhibition of the eubacterial DNA ligase by arylamino compounds. Antimicrob. Agents Chemother. (1999) 43(11):2766-2772.
128. +-dependent DNA ligase by pyridochromanones. J. Biol. Chem. (2003) 278(41):39435-39442.
129. GOOD L, AWASTHI SK, DRYSELIUS R, LARSSON O, NIELSEN PE: Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol(2001) 19(4):360-364.
130. KAISERMAN JA, GROSS MI, GE Y et al.: DNA binding ligands targeting drug-resistant bacteria: structure, activity, and pharmacology. J. Med. Chem. (2003) 46(18):3914-3929.
131. BURLI RW, KAiseRMAN JA, DUAN JX et al.: DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimisation of internal aromatic amino acids. Bioorg. Med. Chem. Lett (2004) 14(9):2067-2072.
132. HU W, BURLI RW, KAIZERMAN JA et al.: DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureus. J. Med. Chem. (2004) 47 18):4352-4355.
133. ALEKSHUN MN, LEVY SB: Targeting virulence to prevent infection: to kill or not to kill? Drug Discov. Today (2004) 1 4):483-489.
134. LOMOVSKAYA O, LEE A, HOSHINO K et al.: Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1999) 43 6):1340-1346.
135. OETHINGER M, KERN WV, JELLEN-RITTER AS, McMURRY LM, LEVY SB: Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. (2000) 44:10-13.
136. PERIC M, BOZDOGAN B, GALDERISI C et al.: Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S. J. Antimicrob. Chemother. (2004) 54(2):393-400.
137. DEAN CR, VISALLI MA, PROJAN SJ, SUM PE, BRADFORD PA: Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. (2003) 47 3):972-978.
138. VISALLI MA, MURPHY E, PROJAN SJ, BRADFORD PA: AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. (2003) 47(2):665-669.
139. LOMOVSKAYA O, WARREN MS, LEE A et al.: Identification and characterisation of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. (2001) 45(1):105-116.
140. NAKAYAMA K, ISHIDA Y, OHTSUKA M et al.: MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds. Bioorg. Med. Chem. Lett. (2003) 13(23):4205-4208.
141. BALL P: Adverse drug reactions: implications for the development of fluoroquinolones. J. Antimicrob. Chemother. (2003) 51(Suppl. 1):21-27.
142. RAY WA, MURRAY KT, MEREDITH S et al.: Oral erythromycin and the risk of sudden death from cardiac causes. N. Engl. J. Med. (2004) 351(11):1089-1096.
143. TRAN TP, ELLSWORTH EL, STIER MA et al.: Synthesis and structural-activity relationships of 3-hydroxyquinazoline-2,4-dione antibacterial agents. Bioorg. Med. Chem. Lett (2004) 14 17):4405-4409.
144. GROSS M, BURLI R, JONES P et al.: Pharmacology of novel heteroaromatic polycycle antibacterials. Antimicrob. Agents Chemother. (2003) 47(11):3448-3457.